B-type natriuretic peptide (BNP) is a 32 amino acid cardiacsynthesized hormone that reduces blood pressure and increases sodium excretion (1 ). Following proteolytic cleavage of proBNP, a 108-amino acid precursor, an Nterminal fragment (NT-proBNP) and BNP are released (2 ). Increased concentrations of BNP and NT-proBNP can be used clinically to monitor heart failure, but a lack of alignment between commercial BNP and NT-proBNP assays (3 ) can lead to confusion when clinicians or laboratorians compare results measured for the same analyte on different instruments. Some of this confusion arises from variable assay specificity regarding what peptides are being measured. We studied whether (a) BNP assays demonstrated crossreactivity with NT-proBNP or proBNP, and (b) whether NTproBNP assays demonstrated crossreactivity with BNP or proBNP, by using 5 commercial BNP and 3 commercial NT-proBNP assays with 2 BNP, 2 NT-proBNP, and 2 proBNP materials.
with 2 BNP, 2 NT-proBNP, and 2 proBNP materials.
The NPs studied were: Peptide Institute synthetic BNP (aa 77-108), Scios human recombinant BNP (aa 77-108), HyTest human recombinant NT-proBNP (aa 1-76), Roche modified (amidated for stabilization) synthetic NTproBNP, HyTest human recombinant proBNP (aa 1-108), and Scios glycosylated human recombinant proBNP. BNP assays evaluated were Abbott Architect, Abbott AxSYM, Bayer Centaur, Biosite Triage, and Beckman Access (Biosite assay packaged for use by Beckman). NT-proBNP assays (all based on Roche reagents) were Dade-Behring Dimension, OrthoClinical Diagnostics Vitros, and Roche Elecsys 2010. All assays, for which epitopes of the antibodies used have been previous described (3 ), were run according to the manufacturers' guidelines. BNP, NT-proBNP, and proBNP materials were diluted with normal (low NP concentration) EDTAplasma pools and lithium-heparin plasma (Dade assay only) pools, collected from healthy donors after institutional review board approval was obtained, to achieve target concentrations of 250, 500, and 1000 ng/L. Baseline BNP and NT-proBNP were quantified first in the pools and then after the pools were spiked with NP peptides. All measurements were performed in duplicate. Baseline BNP or NT-proBNP concentrations were subtracted from each spiked pool measurement. Percent crossreactivity was calculated by dividing the measured concentration for the spiked pool into the expected peptide concentration, multiplying by 100, and then averaging across all 3 expected concentrations.
Recoveries and cross-reactivity percentages between peptides and BNP and NT-proBNP assays are displayed in Table 1 . The BNP assays were more specific for the BNP peptides, with recovery ranging from 79% to 199%, compared to 5% to 38% cross-reactivity to the proBNP peptides and Ͻ1% to 7% cross-reactivity to the NTproBNP peptides. Similarly, the NT-proBNP assays were more specific for the NT-proBNP peptides, showing 47% to 243% recovery, with substantial crossreactivity to proBNP peptides (Ͻ1% to 249%), and no crossreactivity to the BNP peptides (Ͻ1% across all assays).
This study demonstrates that the BNP peptides used do not substantially cross-react with NTproBNP assays, and that the NTproBNP peptides do not substantially cross-react with BNP assays. We confirm that there is substantial cross-reactivity between proBNP peptides and commercially available BNP and NT-proBNP assays. Variations depended on the different sources and types of peptide tested in each assay. We observed minimal crossreactivity with the glycosylated Scios proBNP peptide, compared with substantial cross-reactivity to the nonglycosylated HyTest proBNP peptide with the NTproBNP assays. Glycosylation likely interfered with peptide antibody binding. The mechanisms responsible for different reactivities between the HyTest and Roche NTproBNP peptides using different NT-proBNP assays, which use the same antibodies but different assay architectures, cannot be explained presently. The modest differences in reactivities for the recombinant (Scios) and synthetic (Peptide Institute) BNP materials using different BNP assays also requires additional study; with different assay architectures for the same reagents (Biosite, Beckman) showing diverse recovery.
Little is known about which NP forms are circulating physiologically. The clinical significance of measured cross-reactivities will also depend on the relative quantities of different molecular forms found in individual patient blood. Mass spectrometry has shown that mature BNP1Ϫ32 is absent in severe heart failure patients, but a commercial assay still detected the presence of BNP1Ϫ32 (4 ). Glycosylated forms of proBNP in heart failure patients have also been found, along with uncleaved proBNP (1, 5 ) . Expression of the multiple forms that circulate during acute and chronic heart failure must be investigated in future studies to ensure that commercial assays are measuring the appropriate diagnostic biomarkers for heart failure. Our preliminary observations challenge the analytical field to better characterize what immunoassays measure and challenge the clinical field to better understand what molecules are measured and how to best interpret both BNP and NT-proBNP findings in regard to patient care. 
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To the Editor:
The severity of Hashimoto disease (HD) varies among patients and is difficult to predict when the disease is in the subclinical state and diagnosed by the presence of thyroid-specific autoantibody. Likewise, the intractability of Graves disease (GD) is difficult to predict. Autoimmune thyroid destruction that underlies both diseases is strongly determined by T-cell cytotoxicity, which is activated by interferon (IFN)-␥ (1 ), and the T allele in ϩ874A/T polymorphism of the interferon gamma (IFNG) gene, which promotes increased IFN-␥ production, has been noted more frequently among patients with severe HD (2 ) . Cytokine balance between T-helper 1 (Th1) cytokines, such as IFN-␥, and Th2 cytokines is important in immune regulation (3 ). Therefore, it is possible that Th2 cytokines may also affect the severity of HD and the intractability of GD. To clarify the association of these polymorphisms of the IL4 and IL4RA genes with HD severity and GD intractability, we performed genotyping using a direct sequencing reaction for Ϫ590C/T and TaqMan single-nucleotide polymorphism genotyping assays for Ile50Val in the following individuals: 35 patients Ͻ50 years old with HD who developed permanent hypothyroidism and were treated with L-thyroxine (rapid destruction type; severe HD), 39 euthyroid patients Ͼ50 years old with HD who were untreated (slow destruction type; mild HD), 50 euthyroid patients with GD who remained positive for antithyrotropin receptor antibody (TRAb) despite being on antithyroid drug treatment for Ͼ5 years (intractable GD), 26 patients with GD in remission who had been euthyroid and negative for TRAb for Ͼ2 years after cessation of antithyroid drug treatment, and 47 controls. All patients with HD were positive for antithyroid microsomal antibodies. All patients with GD showed increased TRAb concentrations and thyrotoxicosis when first diagnosed. All study participants were Japanese and unrelated. Written informed consent was obtained from all patients and controls, and the study protocol was approved by the Ethics Committee of Osaka University.
The frequency of the Ϫ590CC genotype in the IL4 gene among the patients with severe HD was 20.0%, whereas the frequency among the patients with mild HD was 0.0% (P ϭ 0.0037) ( Table 1) . If this finding is confirmed prospectively, a high percentage of HD patients with the IL-4 Ϫ590CC genotype would be expected to develop severe disease (hypothyroidism) before 50 years of age. A possible mechanism to explain this phenomenon is that in HD patients with the Ϫ590CC genotype, the proportion of IL-4 -producing T-helper cells is lower than that in HD patients with the Ϫ590TT or Ϫ590CT genotype (4 ), which results in higher activity of inflammatory Th1 cytokines and more rapid progression of thyroid destruction, followed by early development of hypothyroidism. Conversely, we found no association between the Ile50Val polymorphism in the IL4RA gene and HD severity (Table 1 ) despite the receptor activity being different among individuals with this polymorphism. Furthermore, we found no association between these IL4 and IL4RA gene polymorphisms and GD intractability (Table 1) ; however, GD is caused by TRAb and tends to be more intractable in pa-
